Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States

Int J Dermatol. 2024 Apr;63(4):524-525. doi: 10.1111/ijd.16973. Epub 2023 Dec 13.

Authors

Veronica K Emmerich¹, Josiah A Williams¹, Matthew L Hrin¹, Steven R Feldman^{1

2

3

4}, Lindsay C Strowd¹

Affiliations

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
² Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
³ Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.
⁴ Department of Dermatology, University of Southern Denmark, Odense, Denmark.

PMID: 38093434
DOI: 10.1111/ijd.16973

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic* / drug therapy
Humans
Retrospective Studies
Severity of Illness Index
Treatment Outcome
United States

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal